Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Italian Journal of Pediatrics
Published in: Italian Journal of Pediatrics 1/2016

Open Access 01-12-2016 | Review

Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists

Authors: Simone Pisano, Gennaro Catone, Stefania Veltri, Valentina Lanzara, Marco Pozzi, Emilio Clementi, Raffaella Iuliano, Maria Pia Riccio, Sonia Radice, Massimo Molteni, Annalisa Capuano, Antonella Gritti, Giangennaro Coppola, Annarita Milone, Carmela Bravaccio, Gabriele Masi

Published in: Italian Journal of Pediatrics | Issue 1/2016

Login to get access

Abstract

During the past decade, a substantial increase in the use of second generation antipsychotics (SGAs) has occurred for a number of juvenile psychiatric disorders, often as off-label prescriptions. Although they were thought to be safer than older, first generation antipsychotics, mainly due to a lower risk of neurological adverse reactions, recent studies have raised significant concerns regarding their safety regarding metabolic, endocrinological and cardiovascular side effects. Aim of this paper is to update with a narrative review, the latest findings on safety of SGAs in youths. Results suggest that different SGAs may present different safety profiles. Metabolic adverse events are the most frequent and troublesome, with increasing evidences of heightened risk for type II diabetes mellitus. Results are discussed with specific emphasis on possible strategies of an active monitoring, which could enable both paediatricians and child psychiatrists to a possible prevention, early detection, and a timely management of such effects.
Literature
1.
Olfson M, Blanco C, Wang S, Laje G, Correll CU. National trends in the mental health care of children, adolescents, and adults by office-based physicians. JAMA Psychiatry. 2014;71:81.CrossRefPubMed
2.
Olfson M, King M, Schoenbaum M. Treatment of Young People With Antipsychotic Medications in the United States. JAMA Psychiatry. 2015;72:867–74.CrossRefPubMed
3.
Zito JM, Safer DJ, de Jong-van den Berg LT, Janhsen K, Fegert JM, Gardner JF, Glaeske G, Valluri SC. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health. 2008;2(1):26. doi:10.​1186/​1753-2000-2-26.
4.
Piovani D, Clavenna A, Cartabia M, Bonati M. Psychotropic medicine prescriptions in Italian youths: a multiregional study. Eur Child Adolesc Psychiatry. 2016;25(3):235–45.CrossRefPubMed
5.
Kreider AR, Matone M, Bellonci C, et al. Growth in the concurrent use of antipsychotics with other psychotropic medications in Medicaid-enrolled children. J Am Acad Child Adolesc Psychiatry. 2014;53:960–70.CrossRefPubMed
6.
Carton L, Cottencin O, Lapeyre-Mestre M, Geoffroy PA, Favre J, Simon N. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des. 2015;21(23):3280–97.CrossRefPubMed
7.
Pisano S, Catone G, Pascotto A, Gritti A. Second generation antipsychotics in adolescent anorexia nervosa: a new hypothesis of eligibility criteria. J Child Adolesc Psychopharmacol. 2014;24:293–5.CrossRefPubMed
8.
Masi G, Pisano S, Pfanner C, Milone A, Manfredi A. Quetiapine monotherapy in adolescents with bipolar disorder comorbid with conduct disorder. J Child Adolesc Psychopharmacol. 2013;23:568–71.CrossRefPubMedPubMedCentral
9.
Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with Risperidone. J Clin Psychiatry. 2003;64:1039–47.CrossRefPubMed
10.
Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66 suppl 7:29–40.PubMed
11.
Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs. 2011;71:179–208.CrossRefPubMed
12.
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765–73.CrossRefPubMedPubMedCentral
13.
Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21:517–35.CrossRefPubMed
14.
De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26:144–58.CrossRefPubMed
15.
Safer DJ. A comparison of Risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004;24:429–36.CrossRefPubMed
16.
Caccia S. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatr Drugs. 2013;15:217–33.CrossRefPubMed
17.
Pringsheim T, Panagiotopoulos C, Davidson J, Ho J. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2011;3:1–2.
18.
19.
Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, et al. Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med. 2010;164:344–51.CrossRefPubMed
20.
Rodday AM, Parsons SK, Mankiw C, Correll CU, Robb AS, Zima BT, et al. Child and adolescent psychiatrists’ reported monitoring behaviors for second-generation antipsychotics. J Child Adolesc Psychopharmacol. 2015;25:351–61.CrossRefPubMedPubMedCentral
21.
Connolly JG, Toomey TJ, Schneeweiss MC. Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003–2011. Psychiatr Serv. 2015;66:604–09.CrossRefPubMed
22.
Hampton LM, Daubresse M, Chang HY, Alexander GC, Budnitz DS. Emergency department visits by children and adolescents for antipsychotic drug adverse events. JAMA Psychiatry. 2015;72:292–94.CrossRefPubMedPubMedCentral
23.
Arango C, Giráldez M, Merchán-Naranjo J, Baeza I, Castro-Fornieles J, Alda JA, et al. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. J Am Acad Child Adolesc Psychiatry. 2014;53:1179–90.CrossRefPubMed
24.
Noguera A, Ballesta P, Baeza I, Arango C, de la Serna E, González-Pinto A, et al. Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: discontinuation and tolerability. J Clin Psychopharmacol. 2013;33:463–71.CrossRefPubMed
25.
Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119–36.CrossRefPubMedPubMedCentral
26.
Almandil NB, Liu Y, Murray ML, Besag FM, Aitchison KJ, Wong IC. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs. 2013;15:139–50.CrossRefPubMed
27.
Frighi V. Medical side-effects of antipsychotic agents: hyperprolactinaemia and metabolic disorders. In: Mortimer AM, McKenna PJ, editors. Therapeutic strategies in schizophrenia. Oxford: Clinical publishing; 2010. p. 1–19.
28.
Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011;68:609–16.CrossRefPubMed
29.
Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Safe. 2011;34:651–68.CrossRef
30.
Masi G, Milone A, Veltri S, Iuliano R, Pfanner C, Pisano S. Use of Quetiapine in children and adolescents. Paediatr Drugs. 2015;17:125–40.CrossRefPubMed
31.
de Hoogd S, Overbeek WA, Heerdink ER, Correll CU, de Graeff ER, Staal WG. Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of second-generation antipsychotics. J Child Adolesc Psychopharmacol. 2012;22:166–73.CrossRefPubMed
32.
Ebert T, Midbari Y, Shmilovitz R, Kosov I, Kotler M, Weizman A, et al. Metabolic effects of antipsychotics in prepubertal children: a retrospective chart review. J Child Adolesc Psychopharmacol. 2014;24:218–22.CrossRefPubMed
33.
Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with Olanzapine. J Child Adolesc Psychopharmacol. 2012;22:157–65.CrossRefPubMed
34.
Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, Walkup JT, et al. A randomized controlled trial of Risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry. 2012;69:515–28.CrossRefPubMed
35.
Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, et al. Associations among obesity, acute weight gain, and response to treatment with Olanzapine in adolescent schizophrenia. J Child Adolesc Psychopharmacol. 2013;23:522–30.CrossRefPubMedPubMedCentral
36.
Mankoski R, Stockton G, Manos G, Marler S, McQuade R, Forbes RA, et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. J Child Adolesc Psychopharmacol. 2013;23:572–76.CrossRefPubMedPubMedCentral
37.
Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S. Efficacy and safety of Quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2012;22:327–42.CrossRefPubMed
38.
Findling RL, Pathak S, Earley WR, Liu S, DelBello M. Safety, tolerability, and efficacy of Quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study. J Child Adolesc Psychopharmacol. 2013;23:490–01.CrossRefPubMedPubMedCentral
39.
O’Donoghue B, Schäfer MR, Becker J, Papageorgiou K, Amminger GP. Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics. Early Interv Psychiatry. 2014;8:276–80.CrossRefPubMed
40.
Calarge CA, Nicol G, Schlechte JA, Burns TL. Cardiometabolic outcomes in children and adolescents following discontinuation of long-term Risperidone treatment. J Child Adolesc Psychopharmacol. 2014;24:120–29.CrossRefPubMedPubMedCentral
41.
Wink LK, Early M, Schaefer T, Pottenger A, Horn P, McDougle CJ, et al. Body mass index change in autism spectrum disorders: comparison of treatment with Risperidone and Aripiprazole. J Child Adolesc Psychopharmacol. 2014;24:78–82.CrossRefPubMed
42.
Pérez-Iglesias R, Martínez-García O, Pardo-Garcia G, Amado JA, Garcia-Unzueta MT, Tabares-Seisdedos R, et al. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int J Neuropsychopharmacol. 2014;17:41–51.CrossRefPubMed
43.
Galling B, Correll CU. Do antipsychotics increase diabetes risk in children and adolescents? Expert Opin Drug Saf. 2015;14:219–41.CrossRefPubMed
44.
Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen H-L, Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. 2013;62:3232–40.CrossRefPubMedPubMedCentral
45.
Andrade SE, Lo JC, Roblin D, et al. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 2011;128:1135–41.CrossRefPubMed
46.
Nielsen RE, Laursen MF, Vernal DL, BiSGAard C, Jakobsen H, Steinhausen HC, et al. Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case–control study. J Am Acad Child Adolesc Psychiatry. 2014;53:971–79.CrossRefPubMed
47.
Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70:1067–75.CrossRefPubMed
48.
Sohn M, Talbert J, Blumenschein K, Moga DC. Atypical antipsychotic initiation and the risk of type II diabetes in children and adolescents. Pharmacoepidemiol Drug Saf. 2015;24:583–91.CrossRefPubMedPubMedCentral
49.
Rubin DM, Kreider AR, Matone M, Huang YS, Feudtner C, Ross ME, et al. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. JAMA Pediatr. 2015;169:e150285.CrossRefPubMed
50.
51.
Galler A, Bollow E, Meusers M, Bartus B, Näke A, Haberland H, et al. German Federal Ministry of Education and Research (BMBF) Competence Network Diabetes Mellitus. Comparison of glycemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian Diabetes Survey (DPV). Diabetes Care. 2015;38:1051–57.CrossRefPubMed
52.
Pisano S, Gritti A, Catone G, Pascotto A. Antipsychotic-induced dyslipidemia treated with omega 3 fatty acid supplement in an 11-year-old psychotic child: a 1-year follow-up. J Child Adolesc Psychopharmacol. 2013;23:139–41.CrossRefPubMed
53.
De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8:114–26.CrossRefPubMed
54.
Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2009;19:403–14.
55.
Roke Y, van Harten PN. Boot AM, Buitelaar JK. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol. 2009;19:403–14.CrossRefPubMed
56.
Dos Santos Júnior A, Henriques TB, de Mello MP, Neto AP, Paes LA, Torre OH, et al. Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects. J Child Adolesc Psychopharmacol. 2015;25:738–48.CrossRefPubMed
57.
de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015;29:773–99.CrossRefPubMedPubMedCentral
58.
Masi G, Milone A, Stawinoga A, Veltri S, Pisano S. Efficacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder. J Clin Psychopharmacol. 2015;35:587–90.CrossRefPubMed
59.
Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-term use of Risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol. 2006;16:260–72.CrossRefPubMed
60.
Dunbar F, Kusumakar V, Daneman D, Schulz M. Growth and sexual maturation during long-term treatment with Risperidone. Am J Psychiatry. 2004;161:918–20.CrossRefPubMed
61.
Etminan M, Carleton B, Brophy JM. Risperidone and Risk of Gynecomastia in Young Men. J Child Adolesc Psychopharmacol. 2015;25:671–73.CrossRefPubMed
62.
Safer DJ, Calarge CA, Safer AM. Prolactin serum concentrations during Aripiprazole treatment in youth. J Child Adolesc Psychopharmacol. 2013;23:282–89.CrossRefPubMedPubMedCentral
63.
Labellarte MJ, Crosson JE, Riddle MA. The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2003;42:642–50.CrossRefPubMed
64.
Kimura G, Kadoyama K, Brown JB, Nakamura T, Miki I, Nisiguchi K, et al. Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Int J Med Sci. 2015;12:135–40.CrossRefPubMedPubMedCentral
65.
Blair J, Taggart B, Martin A. Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology. J Neural Transm (Vienna). 2004;111:791–15.
66.
Jensen KG, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK. Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry. 2015;54:25–36.CrossRefPubMed
67.
Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. ScientificWorldJournal. 2012;2012:212178.CrossRefPubMedPubMedCentral
68.
Rasimas JJ, Liebelt EL. Adverse Effects and Toxicity of the Atypical Antipsychotics: What is Important for the Pediatric Emergency Medicine Practitioner. Clin Pediatr Emerg Med. 2012;13:300–10.CrossRefPubMedPubMedCentral
69.
Correll CU, Harris J, Figen V, Kane JM, Manu P. Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study. J Child Adolesc Psychopharmacol. 2011;21:365–68.CrossRefPubMedPubMedCentral
70.
Germanò E, Italiano D, Lamberti M, Guerriero L, Privitera C, D’Amico G, et al. ECG parameters in children and adolescents treated with Aripiprazole and Risperidone. Prog Neuro-Psychopharmacol & Biol Psychiat. 2014;51:23–7.CrossRef
71.
Ho JG, Caldwell RL, McDougle CJ, Orsagh-Yentis DK, Erickson CA, Posey DJ, et al. The effects of Aripiprazole on electrocardiography in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2012;22:277–83.CrossRefPubMedPubMedCentral
72.
Gulisano M, Calì PV, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci. 2011;32:1213–7.CrossRefPubMed
73.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.CrossRefPubMed
74.
Alda JA, Muñoz-Samons D, Tor J, Merchán-Naranjo J, Tapia-Casellas C, Baeza I, et al. J Child Adolesc Psychopharmacol. 2016 Jan 18. [Epub ahead of print]
75.
Correll CU, Lops JD, Figen V, Malhotra AK, Kane JM, Manu P. QT interval duration and dispersion in children and adolescents treated with Ziprasidone. J Clin Psychiatry. 2011;72:854–60.CrossRefPubMedPubMedCentral
76.
Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S. Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry. 2014;29:1–10.PubMed
77.
Carbon M, Kapoor S, Sheridan E, Al-Jadiri A, Azzo S, Sarkaria T, et al. Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 s-Generation Antipsychotics. J Am Acad Child Adolesc Psychiatry. 2015;54:718–27.CrossRefPubMed
78.
Garcia-Amador M, Merchán-Naranjo J, Tapia C, Moreno C, Castro-Fornieles J, Baeza I, et al. Neurological Adverse Effects of Antipsychotics in Children and Adolescents. J Clin Psychopharmacol. 2015;35:686–93.CrossRefPubMed
79.
Belvederi Murri M, Guaglianone A, Bugliani M, Calcagno P, Respino M, Serafini G, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D. 2015;15:45–62.CrossRefPubMedPubMedCentral
80.
Neuhut R, Lindenmayer JP, Silva R. Neuroleptic Malignant Syndrome in Children and Adolescents on Atypical Antipsychotic Medication: A review. J Child Adolesc Psychopharmacol. 2009;19:4415–22.CrossRef
81.
Masi G, Milone A, Viglione V, Mancini A, Pisano S. Massive Asymptomatic Creatine Kinase Elevation in youth during antipsychotic drug treatment: case reports and critical review of the literature. J Child Adolesc Psychopharmacol. 2014;10:536–42.CrossRef
82.
83.
84.
Ventriglio A, Gentile A, Baldessarini RJ, Martone S, Vitrani G, La Marca A, et al. Improvements in metabolic abnormalities among overweight schizophrenia and bipolar disorder patients. Eur Psychiatry. 2014;29:402–37.CrossRefPubMed
85.
Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J. Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol. 2015;35:499–09.CrossRefPubMed
86.
Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163:2072–69.CrossRefPubMed
87.
Romo-Nava F, Alvarez-Icaza González D, Fresán-Orellana A, et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord. 2014;16:410–21.CrossRefPubMed
88.
Modabbernia A, Heidari P, Soleimani R. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. J Psychiatr Res. 2014;53:133–40.CrossRefPubMed
89.
Mostafavi A, Solhi M, Mohammadi MR, et al. Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial. Acta Med Iran. 2014;52:734–9.PubMed
90.
Saranac L, Zivanovic S, Radovanovic Z, Kostic G, Markovic I, Miljkovic P. Hyperprolactinemia: different clinical expression in childhood. Horm Res Paediatr. 2010;73:187–92.CrossRefPubMed
91.
Chen JX, Su YA, Bian QT, Wei LH, Zhang RZ, Liu YH, et al. Adjunctive Aripiprazole in the treatment of Risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology. 2015;58:130–40.CrossRefPubMed
92.
Pozzi M, Pisano S, Bertella S, Capuano A, Rizzo R, Antoniazzi S, et al. Persistence in therapy with Risperidone and Aripiprazole in pediatric outpatients: a two-year naturalistic comparison. J Clin Psychiatry Accepted in press.
93.
Whitney Z, Boyda HN, Procyshyn RM, Elbe D, Black T, Eslami A, et al. Therapeutic drug levels of second generation antipsychotics in youth: a systematic review. J Child Adolesc Psychopharmacol. 2015;25:234–45.CrossRefPubMed
94.
Pozzi M, Cattaneo D, Baldelli S, Fucile S, Capuano A, Bravaccio C, et al. Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. Eur J Clin Pharmacol. 2016;72:285–93.CrossRefPubMed
Metadata
Title
Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists
Authors
Simone Pisano
Gennaro Catone
Stefania Veltri
Valentina Lanzara
Marco Pozzi
Emilio Clementi
Raffaella Iuliano
Maria Pia Riccio
Sonia Radice
Massimo Molteni
Annalisa Capuano
Antonella Gritti
Giangennaro Coppola
Annarita Milone
Carmela Bravaccio
Gabriele Masi
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Italian Journal of Pediatrics / Issue 1/2016
Electronic ISSN: 1824-7288
DOI
https://doi.org/10.1186/s13052-016-0259-2

Other articles of this Issue 1/2016

Italian Journal of Pediatrics 1/2016 Go to the issue

Case report

Changes of serum aspergillus galactomannan during hematopoietic stem cell transplantation in children with prior invasive aspergillosis

Research

Genetic and epigenetic alterations in the GNAS locus and clinical consequences in Pseudohypoparathyroidism: Italian common healthcare pathways adoption

Research

Congenital primary adrenal insufficiency and selective aldosterone defects presenting as salt-wasting in infancy: a single center 10-year experience

Research

Celiac crisis in children in Serbia

Research

New insights in the interpretation of array-CGH: autism spectrum disorder and positive family history for intellectual disability predict the detection of pathogenic variants

Review

Monitoring of newborns at high risk for brain injury